Abivax SA Plunges 40% on Cancer Cases in Ulcerative Colitis Drug Trial
Safety concerns over cancer cases in a high-dose cohort overshadow strong Phase 3 efficacy data for obefazimod. Abivax SA shares collapsed up to 40% after releasing Phase 3 data for its ulcerative colitis drug, obefazimod. The trial showed strong efficacy, with clinical re